Will 2018 Be Johnson & Johnson's Best Year Yet?
There are still several weeks left in the year, but Johnson & Johnson (NYSE: JNJ) appears to be on course to generate its second-highest stock performance over the last decade in 2017. A couple of major acquisitions helped the healthcare giant boost revenue to an all-time high in the third quarter.
As the new year approaches, though, investors are more focused on the future than the past. Will 2018 be Johnson & Johnson's best year yet? Probably yes. And probably no.
Image source: Getty Images.
Source: Fool.com
Johnson & Johnson Aktie
148,74 €
-0,67 %
Hohe Buy- und niedrige Sell-Zahlen bei Johnson & Johnson zeigen ein stark positives Sentiment.
Für Johnson & Johnson ergibt sich mit einem Kursziel von 194 € eine mögliche Steigerung von über 20% gegenüber 148.74 €.
